Cingulate Inc Market Cap ($57.82 Million)
Market Cap & Net Worth: Cingulate Inc (CING)
Cingulate Inc market cap. Cingulate Inc (NASDAQ:CING) has a market capitalization of $57.82 Million ($57.82 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21127 globally and #4767 in its home market, demonstrating a -8.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cingulate Inc's stock price $4.72 by its total outstanding shares 12250564 (12.25 Million). Also see CING cash generation efficiency for how efficiently the company converts equity into cash flow.
Cingulate Inc Market Cap History (2021–2026)
Cingulate Inc market cap history from 2021 to 2026. Data shows change from $8.11 Billion to $57.82 Million (-66.88% CAGR). Check current stock price of Cingulate Inc for real-time trading data and today's change.
Index Memberships
Cingulate Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #601 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2011 of 3165 |
Weight: Cingulate Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cingulate Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cingulate Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Cingulate Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CING by Market Capitalization
Companies near Cingulate Inc in the global market cap rankings as of November 4, 2026. Also see CING asset base for a full breakdown of the balance sheet.
Key companies related to Cingulate Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Cingulate Inc (2021–2026)
Market capitalization of Cingulate Inc from 2021 to today. Between 2021 and today, Cingulate Inc's market cap moved from $8.11 Billion to $ 57.82 Million, with a yearly change of -66.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $57.82 Million | +8.76% |
| 2025 | $53.17 Million | -11.97% |
| 2024 | $60.40 Million | -94.63% |
| 2023 | $1.12 Billion | -61.75% |
| 2022 | $2.94 Billion | -63.77% |
| 2021 | $8.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Cingulate Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.82 Million USD |
| MoneyControl | $57.82 Million USD |
| MarketWatch | $57.82 Million USD |
| marketcap.company | $57.82 Million USD |
| Reuters | $57.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more